Xtant Medical (XTNT) Holdings and Dilon Technologies announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon’s Hemoblast Bellows for high-performance hemostasis following certain surgical procedures. Xtant plans to update its full-year 2026 financial guidance in light of the new distribution arrangement in connection with the release of its first quarter 2026 financial results.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Warns of 2026 Profit Hit as One‑Time License Revenue and SimpliMax™ Reimbursements Fade
- Xtant Medical Earnings Call Highlights Profitability Turnaround
- Xtant Medical reports Q4 EPS 0c vs. (2c) last year
- Xtant Medical sees 2026 revenue $95M-$99M, consensus $110.1M
- XTNT Earnings Report this Week: Is It a Buy, Ahead of Earnings?